Vir Biotechnology, Inc. (VIR)

$30.14

+0.23 (+0.77%)
Rating:
Recommendation:
-
Symbol VIR
Price $30.14
Beta 0.151
Volume Avg. 0.83M
Market Cap 4.012B
Shares () -
52 Week Range 18.05-34.969
1y Target Est -
DCF Unlevered VIR DCF ->
DCF Levered VIR LDCF ->
ROE 60.66% Strong Buy
ROA 42.39% Strong Buy
Operating Margin -
Debt / Equity 25.40% Neutral
P/E 3.58 Buy
P/B 1.86 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VIR news


Dr. George Scangos
Healthcare
Biotechnology
NASDAQ Global Select

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.